MyFinsight
Home
Blog
About
AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
$23,791K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from marketable securit...
Deferred revenue
Proceeds from deferred governmen...
Others
Negative Cash Flow Breakdown
Purchase of marketable securitie...
Net loss
Income taxes receivable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-55,427
-43,165
-8,945
-57,119
Depreciation of property and equipment
6,059
5,918
5,182
4,306
Amortization and impairment of intangible assets
-
-
3,732
-
Amortization of intangible assets
931
-1,871
-
940
Amortization of operating lease right-of-use assets
1,793
1,817
1,797
1,990
Stock-based compensation
12,286
12,013
12,904
13,895
Fair value (gain)/loss on contingent consideration
-
-
-
-613
Fair value (gain) loss on contingent consideration and investments
-
-
-4,529
-
Other
-4,642
-2,377
4,319
-1,655
Research fees and grants receivable
-12,264
-13,103
39,666
15,957
Income taxes payable
-
-4,970
-10,051
-12,204
Income taxes receivable
8,024
-
-
-
Accounts payable and accrued liabilities
-7,215
-9,406
5,743
5,070
Deferred revenue
52,162
-8,033
-4,511
-7,045
Deferred grant income
2,097
2,356
804
1,153
Other assets
-3,579
1,741
-3,070
-628
Net cash used in operating activities
25,923
-33,523
-34,743
-52,594
Purchases of property and equipment
2,132
3,831
9,843
8,928
Purchase of marketable securities
141,876
166,308
111,340
33,162
Proceeds from marketable securities
149,755
143,802
119,536
83,099
Receipt of grant funding
5,594
1,361
13,977
918
Distribution from equity accounted investees
-
-
30,113
-
Investment in and loans to equity accounted investees
-
-
251
2,451
Proceeds from repayment of loan from joint venture partner
-
-
-33,268
-
Long-term investments and other assets
0
105
322
2,988
Net cash used in investing activities
11,341
-25,081
75,138
36,488
Payment of liability for in-licensing agreement and other
-
-
6,409
9,240
Proceeds from long-term liabilities and other
-
7,192
10,524
7,554
Proceeds from deferred government contributions and other
13,585
-
-
-
Net cash provided by financing activities
6,393
7,192
4,115
7,372
Effect of exchange rate changes on cash and cash equivalents
-430
-38
290
-544
Decrease in cash and cash equivalents
43,227
-51,450
44,800
-9,278
Cash and cash equivalents and restricted cash, beginning of period
103,799
155,249
110,449
183,615
Cash and cash equivalents and restricted cash, end of period
147,026
103,799
155,249
110,449
Restricted cash included in other assets
1,961
-
-
-
Total cash, cash equivalents, and restricted cash shown on the balance sheet
145,065
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Deferred revenue
$52,162K
(457.23%↑ Y/Y)
Proceeds from marketable
securities
$149,755K
(-50.65%↓ Y/Y)
Proceeds from deferred
government contributions...
$13,585K
Stock-based compensation
$12,286K
(-57.62%↓ Y/Y)
Research fees and grants
receivable
-$12,264K
(-197.92%↓ Y/Y)
Depreciation of property and
equipment
$6,059K
(-32.31%↓ Y/Y)
something is missing
$4,970K
Other
-$4,642K
(-795.95%↓ Y/Y)
Other assets
-$3,579K
(73.39%↑ Y/Y)
Amortization of operating
lease right-of-use...
$1,793K
(-37.37%↓ Y/Y)
Amortization of intangible
assets
$931K
(-49.70%↓ Y/Y)
Receipt of grant funding
$5,594K
(-13.24%↓ Y/Y)
Net cash used in
operating activities
$25,923K
(158.97%↑ Y/Y)
Net cash used in
investing activities
$11,341K
(147.50%↑ Y/Y)
Net cash provided by
financing activities
$6,393K
(146.36%↑ Y/Y)
Canceled cashflow
$72,763K
Canceled cashflow
$144,008K
Canceled cashflow
$7,192K
Decrease in cash and cash
equivalents
$43,227K
(167.66%↑ Y/Y)
Canceled cashflow
$430K
Net loss
-$55,427K
(31.02%↑ Y/Y)
Income taxes
receivable
$8,024K
(205.75%↑ Y/Y)
Accounts payable and
accrued liabilities
-$7,215K
(1.92%↑ Y/Y)
Deferred grant income
$2,097K
(24.75%↑ Y/Y)
Purchase of marketable
securities
$141,876K
(-51.34%↓ Y/Y)
Purchases of property and
equipment
$2,132K
(-91.12%↓ Y/Y)
something is missing
-$7,192K
Effect of exchange rate
changes on cash and cash...
-$430K
(-131.83%↓ Y/Y)
Buy us a coffee